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Unpainfully Sweet 
Khoi Nguyen, DO and Alex Schafir, MD FACP
Providence St. Vincent, Internal Medicine Residency, Portland, Oregon
Sweet's syndrome (ss), or  acute febrile neutrophilic dermatosis, 
is characterized by sudden onset of fever, leukocytosis and erythematous 
plaques or nodules infiltrated by neutrophils. There are three main 
clinical settings in which Sweet's syndrome has been described:
The diagnosis of Sweet’s syndrome often has a temporal association with 
the discovery or relapse of cancer as reported in this case.  
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A 64-year-old woman with recurrent breast cancer on targeted and 
hormonal therapy presented to the ED with acute onset of fever and 
diffuse non-tender body rash. 
Vitals suggested sepsis and she was treated with broad spectrum 
antibiotics.  A chest xray, viral panel, blood cultures, echocardiogram and 
urinalysis were unrevealing. 
Erythrocyte sedimentation rate and C-reactive protein were elevated.  
There were 90% neutrophils.  
When her erythematous plaques became vesicular, she was treated with 
IV Acyclovir for possible disseminated zoster. This was discontinued when 
biopsy for HSV/HZV returned negative. 
Skin biopsy, however, showed dense neutrophilic infiltration consistent 
with Sweet Syndrome.  Treatment with prednisone resulted in rapid 
clinical improvement. 
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Figure a-e. Presenting lesions
Figure f. Biopsy showing neutrophilic infiltrate. 
Classical SS Drug Induced SS Malignancy 
Associated SS
 Infection (URI and GI)
 Inflammatory (UC and Crohns) 
 Pregnancy 
 Granulocyte-colony stimulating 
factor 
 Furosemide, Nitrofurantoin, 
Bactrim 
 Hematologic (AML)
 Solid (Breast, GU, GI)
Major Criteria:
 Abrupt onset of painful erythematous plaques or nodules
 Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis
Minor Criteria:
 Pyrexia >38°C
 Association with underlying hematologic or visceral malignancy, inflammatory disease or pregnancy, OR 
preceded by upper respiratory infection, gastrointestinal infection, or vaccination
 Excellent response to treatment with systemic glucocorticoids or potassium iodide
 Abnormal laboratory values at presentation (three of four of the following: erythrocyte sedimentation rate >20 
mm/hour, positive C-reactive protein, >8000 leukocytes, >70 percent neutrophils)
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Historically, the diagnosis of SS requires the presence of painful erythematous lesions (both Major Criteria and 
two of four Minor Criteria). The absence of pain and tenderness in this patient made the diagnosis 
challenging.  After extensive evaluation to rule out infectious etiology, it was revealed through skin biopsy that 
her syndrome was more consistent with Sweet Syndrome despite having non-tender lesions. Given her recent 
recurrence of breast cancer, it was thought that her SS was more consistent with Malignancy-Associated SS 
(MASS) subtype. 
MASS is most commonly associated with hematological malignancies such as AML, but also occurs coincident 
with solid tumors, such as carcinomas of GU organs, breast, and GI tract. In patients with a previous history 
of cancer, the diagnosis of SS usually heralds the onset of recurrence. Sweet syndrome may precede, follow, 
or appear concurrently with a malignancy. This patient was found to have a recurrence of breast cancer in the 
form of bone metastases two months prior to admission. 
In summary, this case demonstrates an atypical painless presentation of SS and how evaluation for 
malignancy is indicated for patients with SS, particularly when there is an absence of other explanations such 
as recent infection, inflammatory disease or drug exposure. 
Treatment : Prednisone  0.5mg to 1mg/kg per day. Symptoms usually improve within 48 hours and skin 
lesions resolves within 1 to 2 weeks. Steroid is then taper over course of 4 to 6 weeks. 
